An LDH-based prognostic model for extensive-stage small-cell lung cancer patients treated with chemo-immunotherapy and consolidative thoracic radiotherapy - Takeaways - MDSpire

An LDH-based prognostic model for extensive-stage small-cell lung cancer patients treated with chemo-immunotherapy and consolidative thoracic radiotherapy

  • By

  • Yunuo Zhao

  • Yuchi Zou

  • Shengxin Zhang

  • Yu Zhang

  • Xueyan Zhou

  • Shen Li

  • Yuwen Zhou

  • May 20, 2026

  • 0 min

Share

  • 1

    Serum lactate dehydrogenase (LDH) is an independent prognostic marker for overall survival in extensive-stage small-cell lung cancer (ES-SCLC) patients.

  • 2

    Elevated LDH levels (>250 U/L) are associated with significantly poorer overall survival compared to lower levels (≤250 U/L) in ES-SCLC patients.

  • 3

    A prognostic nomogram incorporating LDH, AJCC stage, systemic immune-inflammation index, and immunotherapy status was developed for predicting overall survival.

  • 4

    The nomogram demonstrated moderate discriminative ability with an area under the curve of 0.731 at 12 months and 0.694 at 24 months.

  • 5

    This study highlights the potential of LDH as a simple biomarker for risk stratification and personalized management in ES-SCLC treatment.

Original Source(s)

An LDH-based prognostic model for extensive-stage small-cell lung cancer patients treated with chemo-immunotherapy and consolidative thoracic radiotherapy

  • by Yunuo Zhao, Yuchi Zou, Shengxin Zhang, Yu Zhang, Xueyan Zhou, Shen Li, Yuwen Zhou

  • May 20, 2026

Related Content

FEBAIR microsurgical principles in meningiomas and recurrence: a long-term follow-up series

High-grade astrocytoma with piloid features: a case report of comprehensive management

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment